{"filings":[{"id":563638,"accession_number":"0001193125-26-233375","cik":2114044,"company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","form_type":"8-K","filed_at":"2026-05-21T11:05:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.","Cash $163.5M at March 31; with $317.2M net IPO proceeds, runway into 2029.","Completed IPO in May 2026: 19.26M shares at $18.00, raising $346.7M gross; now listed on Nasdaq under COAG.","FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.","Preparing Phase 3 pivotal trial for sutacimig in GT expected H2 2026; data from Factor VII and VWD trials in late 2026/early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1366133260.9090908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12722,"accession_number":"0001193125-26-216699","cik":2114044,"company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","form_type":"8-K","filed_at":"2026-05-11T20:01:15+00:00","items":["5.02"],"status":"ready","headline":"Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.","Resignation not related to any disagreement with the Company on operations, policies or practices.","No replacement director announced; Board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1366133260.9090908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97748,"accession_number":"0001193125-26-203988","cik":2114044,"company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.","Gross proceeds of $346.7 million before underwriting discounts and estimated offering expenses.","Common stock begins trading on Nasdaq Global Select Market under ticker 'COAG'.","Restated certificate increases authorized common shares to 400M, establishes classified board with staggered three-year terms.","Stockholder written consent and special meeting rights eliminated; exclusive forum provisions adopted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1366133260.9090908,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}